LIXT Stock News & Sentiment

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial  by Major Pharma Company-

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference-

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing